Role of biomarkers in antimicrobial stewardship: physicians’ perspectives

키워드

참고문헌 (74)

1. Barlam TF, "Implementing an antibiotic stewardship program : guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America", Clin Infect Dis, 62, pp.e51~e77 (2016)
2. Cheong HS, "Developing core elements and checklist items for implementing antimicrobial stewardship programs in Korean general hospitals : a modified Delphi survey", Infect Chemother, 55, pp.59~68 (2023)
3. Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework", Clin Pharmacol Ther, 69, pp.89~95 (2001)
4. Póvoa P, "How to use biomarkers of infection or sepsis at the bedside : guide to clinicians", Intensive Care Med, 49, pp.142~153 (2023)
5. Maves RC, "Uses of procalcitonin as a biomarker in critical care medicine", Infect Dis Clin North Am, 36, pp.897~909 (2022)
6. Tang BM, "Accuracy of procalcitonin for sepsis diagnosis in critically ill patients : systematic review and meta-analysis", Lancet Infect Dis, 7, pp.210~217 (2007)
7. Ramírez P, "Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia", Crit Care Med, 39, pp.2211~2217 (2011)
8. Self WH, "Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with community-acquired pneumonia", Chest, 150, pp.819~828 (2016)
9. Gewurz H, "C-reactive protein and the acute phase response", Adv Intern Med, 27, pp.345~372 (1982)
10. Póvoa P, "C-reactive protein as a marker of infection in critically ill patients", Clin Microbiol Infect, 11, pp.101~108 (2005)
11. García Vázquez E, "C-reactive protein levels in community-acquired pneumonia", Eur Respir J, 21, pp.702~705 (2003)
12. Póvoa P, "C-reactive protein : a valuable marker of sepsis", Intensive Care Med, 28, pp.235~243 (2002)
13. Barlam TF, "SHEA statement on antibiotic stewardship in hospitals during public health emergencies", Infect Control Hosp Epidemiol, 43, pp.1541~1552 (2022)
14. Ito A, "An algorithm for PCT-guided antimicrobial therapy : a consensus statement by Japanese experts", Clin Chem Lab Med, 61, pp.407~411 (2022)
15. Yoon YK, "Guidelines on implementing antimicrobial stewardship programs in Korea", Infect Chemother, 53, pp.617~659 (2021)
16. Park DW, "Implementation of procalcitonin in antibiotic stewardship : derivation of a consensus algorithm for procalcitonin use in clinical practice", Infect Chemother, 54, pp.621~636 (2022)
17. Bouadma L, "Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units(PRORATA trial) : a multicentre randomised controlled trial", Lancet, 375, pp.463~474 (2010)
18. Layios N, "Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients", Crit Care Med, 40, pp.2304~2309 (2012)
19. Schuetz P, "Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections : the ProHOSP randomized controlled trial", JAMA, 302, pp.1059~1066 (2009)
20. Christ-Crain M, "Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia : a randomized trial", Am J Respir Crit Care Med, 174, pp.84~93 (2006)
21. Long W, "Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia", Respirology, 16, pp.819~824 (2011)
22. Cals JW, "Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections : cluster randomised trial", BMJ, 338, pp.b1374~ (2009)
23. Little P, "Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections : a multinational, cluster, randomised, factorial, controlled trial", Lancet, 382, pp.1175~1182 (2013)
24. Boere TM, "Effect of C reactive protein point-of-care testing on antibiotic prescribing for lower respiratory tract infections in nursing home residents : cluster randomised controlled trial", BMJ, 374, pp.n2198~ (2021)
25. National Institute for Health and Care Excellence, "COVID-19rapid guideline: antibiotics for pneumonia in adults in hospital", National Institute for Health and Care Excellence, ~ (2020)
26. Hessels LM, "Procalcitonin-guided antibiotic prescription in patients with COVID-19 : a multicenter observational cohort study", Chest, 164, pp.596~605 (2023)
27. Kiapi G, "Successful antibiotic stewardship in the electronic era", JAC Antimicrob Resist, 5, pp.dlad072~ (2023)
28. Williams EJ, "Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2infection : a retrospective cohort study", J Hosp Infect, 110, pp.103~107 (2021)
29. Harte E, "Procalcitonin values fail to track the presence of secondary bacterial infections in COVID-19 ICU patients", Antibiotics(Basel), 12, pp.709~ (2023)
30. Vanhomwegen C, "Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit", Ir J Med Sci, 190, pp.1649~1652 (2021)
31. Dolci A, "Searching for a role of procalcitonin determination in COVID-19 : a study on a selected cohort of hospitalized patients", Clin Chem Lab Med, 59, pp.433~440 (2020)
32. Heer RS, "Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection", Ann Clin Biochem, 58, pp.520~527 (2021)
33. Langford BJ, "Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis", Clin Microbiol Infect, 26, pp.1622~1629 (2020)
34. Pink I, "C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19", Infection, 49, pp.935~943 (2021)
35. Houghton R, "C-reactive protein-guided use of procalcitonin in COVID-19", JAC Antimicrob Resist, 3, pp.dlab180~ (2021)
36. Kooistra EJ, "Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients", Crit Care, 25, pp.281~ (2021)
37. Stolz D, "Antibiotic treatment of exacerbations of COPD : a randomized, controlled trial comparing procalcitonin-guidance with standard therapy", Chest, 131, pp.9~19 (2007)
38. Christ-Crain M, "Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections : cluster-randomised, single-blinded intervention trial", Lancet, 363, pp.600~607 (2004)
39. Mathioudakis AG, "Procalcitonin to guide antibiotic administration in COPD exacerbations : a meta-analysis", Eur Respir Rev, 26, pp.160073~ (2017)
40. Butler CC, "C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations", N Engl J Med, 381, pp.111~120 (2019)
41. Bafadhel M, "Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD", Chest, 139, pp.1410~1418 (2011)
42. Maisel A, "Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea : results from the BACH(Biomarkers in Acute Heart Failure)trial", Eur J Heart Fail, 14, pp.278~286 (2012)
43. Demissei BG, "Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients", Int J Cardiol, 204, pp.164~171 (2016)
44. Mueller C, "Procalcitonin and the early diagnosis of infective endocarditis", Circulation, 109, pp.1707~1710 (2004)
45. Yu CW, "Role of procalcitonin in the diagnosis of infective endocarditis : a meta-analysis", Am J Emerg Med, 31, pp.935~941 (2013)
46. Picariello C, "Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention", Intern Emerg Med, 4, pp.403~408 (2009)
47. Remskar M, "Procalcitonin in patients with acute myocardial infarction", Wien Klin Wochenschr, 114, pp.205~210 (2002)
48. Schuetz P, "Procalcitonin : a new biomarker for the cardiologist", Int J Cardiol, 223, pp.390~397 (2016)
49. Siriwardena AK, "A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis(PROCAP) : a single-centre, patient-blinded, randomised controlled trial", Lancet Gastroenterol Hepatol, 7, pp.913~921 (2022)
50. Cai Y, "A procalcitonin-based guideline promotes shorter duration of antibiotic use safely in acute pancreatitis", J Infect, 69, pp.412~415 (2014)
51. Chen L, "The diagnostic value of procalcitonin in patients with severe acute pancreatitis : a meta-analysis", Turk J Gastroenterol, 33, pp.722~730 (2022)
52. Shajiei A, "Impact of reduced antibiotic treatment duration on antimicrobial resistance in critically ill patients in the randomized controlled SAPS-trial", Front Med(Lausanne), 10, pp.1080007~ (2023)
53. Kyriazopoulou E, "Procalcitonin to reduce long-term infection-associated adverse events in sepsis. a randomized trial", Am J Respir Crit Care Med, 203, pp.202~210 (2021)
54. de Jong E, "Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients : a randomised, controlled, open-label trial", Lancet Infect Dis, 16, pp.819~827 (2016)
55. Bloos F, "Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock : a randomized clinical trial", JAMA Intern Med, 176, pp.1266~1276 (2016)
56. Hochreiter M, "Procalcitonin to guide duration of antibiotic therapy in intensive care patients : a randomized prospective controlled trial", Crit Care, 13, pp.R83~ (2009)
57. Lam SW, "Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients : focus on subgroups based on antibiotic initiation, cessation, or mixed strategies", Crit Care Med, 46, pp.684~690 (2018)
58. Sligl WI, "Antimicrobial stewardship, procalcitonin testing, and rapid blood-culture identification to optimize sepsis care in critically ill adult patients : a quality improvement initiative", Antimicrob Steward Healthc Epidemiol, 3, pp.e107~ (2023)
59. Borges I, "Duration of antibiotic therapy in critically ill patients : a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers", Crit Care, 24, pp.281~ (2020)
60. Oliveira CF, "Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis : a randomized trial", Crit Care Med, 41, pp.2336~2343 (2013)
61. Ali WA, "A randomized trial to compare procalcitonin and C-reactive protein in assessing severity of sepsis and in guiding antibacterial therapy in Egyptian critically ill patients", Ir J Med Sci, 190, pp.1487~1495 (2021)
62. Yaegashi Y, "Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis", J Infect Chemother, 11, pp.234~238 (2005)
63. Turgman O, "Host response biomarkers for sepsis in the emergency room", Crit Care, 27, pp.97~ (2023)
64. Lee S, "Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock : a prospective observational study according to the Sepsis-3 definitions", BMC Infect Dis, 22, pp.8~ (2022)
65. Xiao H, "Potential value of presepsin guidance in shortening antibiotic therapy in septic patients : a multicenter, prospective cohort trial", Shock, 57, pp.63~71 (2022)
66. Stolz D, "Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia : a randomised study", Eur Respir J, 34, pp.1364~1375 (2009)
67. Ogasawara T, "Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake", Respir Investig, 52, pp.107~113 (2014)
68. Hellyer TP, "Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia(VAPrapid2) : a randomised controlled trial and process evaluation", Lancet Respir Med, 8, pp.182~191 (2020)
69. Conway Morris A, "Diagnostic importance of pulmonary interleukin-1beta and interleukin-8in ventilator-associated pneumonia", Thorax, 65, pp.201~207 (2010)
70. Srinivasan P, "Safety of procalcitonin guided early discontinuation of antibiotic therapy among children receiving cancer chemotherapy and having low-risk febrile neutropenia : a randomized feasibility trial(ProFenC Study)", Pediatr Hematol Oncol, 41, pp.89~102 (2024)
71. Schuetz P, "Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions : a poststudy survey", Eur J Clin Microbiol Infect Dis, 29, pp.269~277 (2010)
72. Hohn A, "Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit : a retrospective before-and-after analysis", Infection, 43, pp.405~412 (2015)
73. Collins CD, "Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis", Am J Health Syst Pharm, 76, pp.1219~1225 (2019)
74. Gluck E, "Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States : a retrospective, observational study", PLoS One, 13, pp.e0205924~ (2018)

관련 논문AI추천